ACUTE MYELOID LEUKEMIA, IN RELAPSE

This early-stage trial tests a new treatment called CD371-YSNVZ-IL18 CAR T cells for people with acute myeloid leukemia (AML) that has come back or not responded to standard therapy. The main goal is to find the safest dose and see what side effects occur. About 15 participants w…

This early-phase study tests a new treatment for adults with acute myeloid leukemia (AML) that has come back or not responded to standard therapy. The treatment combines specially trained natural killer (NK) immune cells with a drug called atezolizumab. The main goal is to find a…

This early-stage study tests an experimental drug called APL-4098, alone or with standard treatments, in adults with acute myeloid leukemia (AML) or related blood disorders. The goal is to find a safe dose and see if it shrinks cancer. About 100 people will take part.

This early-phase trial is testing a new approach for acute myeloid leukemia (AML) that combines a personalized vaccine made from the patient's own immune and leukemia cells, specially trained T-cells, and two standard chemotherapy drugs. The study aims to see if this combination …

This early-stage trial tests a new drug called C6 ceramide nanoliposome (Ceraxa) in 15 adults with acute myeloid leukemia that has come back or not responded to treatment. The drug is given by IV twice a week, and the main goal is to check safety and find the right dose. It is to…

This early-stage trial is testing an experimental drug called ziftomenib alongside standard treatments for acute myeloid leukemia (AML) in people with specific gene mutations. About 420 participants with newly diagnosed or relapsed AML will be assigned to one of three treatment a…

This early-phase trial is testing whether adding the drug venetoclax to a standard chemotherapy regimen can help children and young adults whose acute myeloid leukemia (AML) has come back or not responded to treatment. About 40 participants will receive different doses of venetoc…

This early-stage trial is testing a combination of two oral drugs—bomedemstat and venetoclax—in adults whose acute myeloid leukemia (AML) has returned or not responded to standard treatment. The main goal is to find the safest dose and check for side effects. Up to 18 participant…

This early-stage study tests a new treatment called SC-DARIC33 for children and young adults up to age 30 whose acute myeloid leukemia (AML) has returned or not responded to standard therapy. The treatment uses the patient's own immune cells, which are modified in the lab to bett…

This early-stage trial tests a new treatment called MT-401-OTS for people with relapsed acute myeloid leukemia or high-risk myelodysplastic syndromes. The therapy uses donor immune cells specially trained to attack cancer, and is given as a one-time infusion. The main goals are t…

This study tests a new drug called ARD103 in adults whose acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) has come back or not responded to standard treatments. The main goals are to check safety and find the best dose, while also seeing if the drug can shrink or c…

This early-phase trial is testing a new drug called AB8939, given daily through a vein, for people with acute myeloid leukemia that has come back or not responded to standard treatments. About 78 participants will receive AB8939, sometimes with another drug called venetoclax. The…

This observational study will follow 4,000 people whose acute myeloid leukemia has returned or not responded to treatment. Researchers will collect data from routine care to understand survival rates and treatment patterns over up to 4 years. No new drugs are being tested; the go…